© 2026 Sparkline Capital LP. All rights reserved.

For informational purposes only. Not investment advice or a recommendation of any security or fund. Past performance is not indicative of future results.

Terms of Service | Privacy Policy | Disclosures | Methodology |

ANALYTICS
AnalysisScreenerGroups

Selection

Selected (1/4)

HQL

Seeded with the selected fund at 100%

Benchmark

Pick one fund or composite — returns and exposures render in excess of it

Peer Universe

Reference set for percentile ranks and factor bars

Equity Funds · 5,640 total

ANALYTICS
AnalysisScreenerGroups

HQL

Sector

abrdn Life Sciences Investors

AUM
$689M
Inception
5/1/1992
1Y Return
+25.8%86th %ilevs 5,640 asset-class peers
·

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Time Series
–

Performance

NameCumulative ReturnAnn. ReturnAnn. VolSharpeMax DD
HQL
abrdn Life Sciences Investors
25.8%25.8%23.0%0.96-20.3%
ⓘ Methodology

ETF performance based on market prices. Drag on chart to select period. Sharpe Ratio uses the one-month T-bill as the risk-free rate. From 10/7/2025 to 10/7/2026.

Trailing Returns

Name
YTD1D5D1M3M6M1Y2Y3Y5YMAX
HQL
abrdn Life Sciences Investors
14.8%0.0%-6.1%-14.9%-12.5%10.0%25.8%23.9%26.9%8.6%9.3%
ⓘ Methodology

ETF performance based on market prices. Returns for periods greater than one year are annualized. As of 10/7/2026.

Annual Returns

Name
1992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025YTD
HQL
abrdn Life Sciences Investors
-2.5%*-16.2%-26.5%66.7%3.8%0.6%-6.3%81.4%27.4%14.4%-36.0%42.2%10.9%11.8%-6.7%7.3%-27.9%14.8%20.3%16.4%37.3%52.1%31.3%5.8%-19.5%25.4%-16.2%25.5%23.7%5.5%-19.2%4.2%11.0%45.5%14.8%
ⓘ Methodology

* partial year — the series ran for only part of it (its first year, or the year it closed); the figure is the return over the part it did run. ETF performance based on market prices. As of 10/7/2026.

Correlation Matrix

Benchmark

Select a second series, or to correlate with the seven research factors.

Factor Regression

Name
Ann. αβ MKTβ SMBβ HMLβ RMWβ CMAβ UMDβ iHMLR²Obs
HQLUS
abrdn Life Sciences Investors
34.5%0.34*0.43**-0.41**-0.51**0.210.070.090.34226
ⓘ Methodology

ETF performance based on market prices. US factor set. Daily OLS of excess return (fund − T-bill) on factor spread returns over the selected date range, intersected with each series' history. Bold with * |t| ≥ 1.96, ** |t| ≥ 2.58. Cell shading tracks each loading's t-stat. Betas are returns-based — compare with the holdings-based factor scores below. Factor returns are long-short spread returns (© Ken French, Dartmouth). From 10/7/2025 to 8/31/2026.

SnapshotAs ofvsⓘ

Fund ProfileSector

Registrant
Type
ETF
Asset Class
Equity
Region
Equity Size & Style
Peer Group Benchmark
Peer Group
Sector - Biotech (25 peers)
1Y Peer Percentile
20
3Y Peer Percentile
71
AUM
$689M
3Y Flow
+15.1%
Inception
5/1/1992
Holdings (Reported)
154
Equity
98%
Derivatives
3%
Option Notional
-1%
Strategy Summary

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

ⓘ Methodology

Expense ratio and its components from the prospectus fee table, else the SEC annual shareholder report, else market data. Yield as of 10/6/2026, AUM 6/30/2026. Holdings, asset class, style, peer group and exposures as of 6/30/2026. Summary may be from an older prospectus.

Equity Size & Style Map

Based on equity exposure only (79% of total assets).

LargeMidSmall
1%
1%
3%
1%
1%
12%
-
-
81%
Large
ValueCoreGrowth
Size
Large
6%
Mid
13%
Small
81%
Style
Value
2%
Core
2%
Growth
96%
ⓘ Methodology

Equity size and style definitions. Size: each holding is scored against its own market's size curve — Large above $61.7B in the US and $21.4B elsewhere, Small below $10.8B worldwide — and a fund sits at the weighted average of its holdings. Style: each holding's Traditional Value score is ranked against stocks of the same region and size, and a fund sits at the weighted average of those ranks. Both are relative measures — where a holding stands among comparable stocks, not an absolute threshold. The dollar lines are recomputed from total market capitalisation each time the data is refreshed; the shares of the market they mark are what stay fixed. Cell shading and percentages: share of classified holdings weight per box. The grid and the dot are built from one set of per-holding scores — the dot is their weighted average — so they describe the same book at two levels of detail. The Size and Style bars are the grid's row and column totals. Holdings as of 6/30/2026. Stock-level data as of 8/31/2026.

Composite FactorsRef: Equity Funds

Based on equity exposure only (79% of total assets).

Intangible Value16.0
Traditional Value0.0
Small-Cap88.4
Quality1.1
Momentum93.1
ⓘ Methodology

Hover or click for factor definitions. Weighted average of underlying company-level values with weights equal to position size. Ranked within the clean equity fund universe, one entry per fund series (lowest: 0, highest: 100; the middle of the range is denser than the ends). Blue dots mark the fund; the shaded band spans the Equity Funds class 25th–75th percentile of scores, notched at the median. Holdings as of 6/30/2026. Stock-level data as of 8/31/2026.

Factor DetailsRef: Equity Funds

Based on equity exposure only (79% of total assets).

Valuation
Book-to-Price (NTM)15.5
Sales-to-Price (NTM)5.7
Earnings-to-Price (NTM)-5.1
Innovation/IP
R&D / Mkt Cap3.7
Patents / Mkt Cap1.1
Brand
Sales & Marketing / Mkt Cap1.0
Trademarks / Mkt Cap0.10
Human Capital
PhD Employees / Mkt Cap22.2
Top University Alumni / Mkt Cap23.6
Politics
Lobbying Spend / Mkt Cap28.8
AI
AI Employees / Mkt Cap0.60
ⓘ Methodology

Hover or click for factor definitions. Weighted average of underlying company-level values with weights equal to position size. Solid blue dots mark the fund's position within the clean equity fund universe (5th–95th percentile scale); the shaded band spans the fund's broad class (Equity Funds) 25th–75th percentile, notched at the median. Holdings as of 6/30/2026. Stock-level data as of 8/31/2026. Expense ratio, yield, and turnover as of 10/6/2026. AUM as of 6/30/2026.

Asset Class Exposure

Equity88.9%
Fixed Income7.1%
Cash & Short-Term1.3%
Other2.7%
Short positions of 0.1% of net assets are not shown.ⓘ Methodology

Shares of the fund's long book, from the asset category each position is filed under. The short book is stated under the card and never netted into a slice: a pie cannot draw a negative, and folding a hedge into the class it offsets would make it look like more of that class. Other is everything we could not name as an asset class: holdings the filing itself labels as other, derivative positions at the market value the filing reports rather than at notional, and funds held inside this fund whose own holdings we could not read.

Country Exposure

Level
85.6%
85.6%
14.4%
8.4%
2.5%
1.5%
Other1.9%
ⓘ Methodology

Shares are percentages of the holdings that carry a country, not portfolio weights. Holdings as of 6/30/2026. Stock-level data as of 8/31/2026.

Sector Exposure

Level

Based on equity exposure only (79% of total assets).

100.0%
ⓘ Methodology

Shares are percentages of the fund's classified holdings — every position we can identify, with cash and unidentified positions excluded — not portfolio weights. Holdings as of 6/30/2026. Stock-level data as of 8/31/2026.

Thematic Exposure

Based on equity exposure only (79% of total assets).

AI Composition

Infrastructure1.3%
Early Adopter6.6%
Laggard92.0%

Magnificent 7

Magnificent 70.0%
Non-Magnificent 7100.0%

Old vs New Economy

Old Economy0.0%
New Economy100.0%

Globalization

Multinational10.4%
Exporter0.0%
Importer24.6%
Domestic65.0%

China Exposure

China/HK Domiciled0.0%
Revenue & Operations0.0%
Operations Only2.5%
Revenue Only0.0%
No Material Exposure97.5%

Company Size

Mega (>$500B)0.0%
Large ($70–500B)2.5%
Mid ($10–70B)20.3%
Small ($1–10B)64.5%
Micro (<$1B)12.7%
ⓘ Methodology

Shares are percentages of the fund's classified equity book, renormalized so each split sums to 100% (the equity book is 98% of net assets) — they are not portfolio weights. China exposure: domiciled = incorporated in China or Hong Kong, falling back to the filing's country for holdings outside the stock model. Among the rest, revenue = ≥15% of revenue derived from China; operations = ≥3% of LinkedIn-tracked workforce in China, or ≥2 identified Chinese suppliers making up ≥12% of those identified. China revenue is estimated where segment reporting is absent. Company size bands by holding market cap: Mega >$500B, Large $70–500B, Mid $10–70B, Small $1–10B, Micro <$1B. Old vs New Economy partitions Sparkline's 48 industries: New = technology, internet platforms and entertainment, e-commerce, payments, pharma/biotech/medtech, and renewable energy; Old = everything else. Shares are of classified holdings and sum to 100%. China shares are of total equity weight. Size shares are of scored holdings weight. Holdings as of 6/30/2026. Stock-level data as of 8/31/2026.

Holdings

See more rows — create a free account▾

154 positions (top 10 shown, create for full holdings)

#NameTickerWeight %SectorIndustryCountry
1uniQureQURE
3.77
HealthcareBiotech & Life SciNLD
2InsmedINSM
3.22
HealthcareBiotech & Life SciUSA
3VeraDermicsMANE
3.06
HealthcareBiotech & Life SciUSA
4PersonalisPSNL
3.00
HealthcareBiotech & Life SciUSA
5ArgenxARGX
2.64
HealthcareBiotech & Life SciNLD
6Dyne TherapeuticsDYN
2.58
HealthcareBiotech & Life SciUSA
7Denali TherapeuticsDNLI
2.46
HealthcareBiotech & Life SciUSA
8VeradermicsMANE
1.95
HealthcareBiotech & Life SciUSA
9AbivaxABVX
1.90
HealthcareBiotech & Life SciFRA
10ImmunovantIMVT
1.89
HealthcareBiotech & Life SciUSA
ⓘ Methodology

Holdings as of 6/30/2026. Stock-level data as of 8/31/2026.

ConcentrationRef: Equity Funds

Total Holdings154
Effective Holdings68
Top 10 Weight26.4%
Max Position3.8%
Top Sector (of Net Assets)81%
Top Country (of Net Assets)83%
ⓘ Methodology

Hover or click for definitions. Solid blue dots mark the fund: percentage rows on a 0–100% scale, holdings counts log-scaled across the clean-universe 5th–95th percentile range. The shaded band spans the fund's broad class (Equity Funds) 25th–75th percentile, notched at the median. Holdings as of 6/30/2026.

Benchmark DifferentiationRef: Equity Funds

vs SPYBroad Benchmark
Active Share99.4%
Tracking Error20.3%
Benchmark Correlation0.43
vs IWOStyle Benchmark
Active Share94.3%
Tracking Error21.7%
Benchmark Correlation0.52
ⓘ Methodology

One sub-card per benchmark: the market primary, then the style secondary — the gap between them is the style sleeve itself. Both anchors are Sparkline-inferred (market from asset class and region, style from the holdings size-and-style map), not the fund's official prospectus benchmark. Solid blue dot marks the fund; the shaded band spans the reference set's 25th–75th percentile, notched at the median (band follows the Peer Universe selector). Active Share compares the fund's book with the benchmark's, share for share; Tracking Error is the annualized daily deviation over the trailing two years (ruler runs to just past the universe's 95th percentile, or past the fund's own figure where that is larger); Benchmark Correlation is the plain daily correlation over the trailing year. Hover the labels for full definitions.

Peer Group Rank

See All Peer Groups
Metric
HQL
abrdn Life Sciences Investors
Peer Group
25 funds
Peer Asset Class
5,640 funds
YTD Return
14.84%16.99%3211.63%68
1Y Return
25.78%35.56%2014.44%86
3Y Return (Ann.)
26.92%21.55%7118.50%91
5Y Return (Ann.)
8.63%5.50%778.64%50
Expense Ratiohigher = cheaper
---
ⓘ Methodology

Sparkline's own holdings-based peer taxonomy (40 share classes across 25 funds). One share class shown per fund — the exchange-listed class where the SEC series has one, else its longest-history class; percentile ranks and medians are computed against the same deduped set. Quartile chips fill the layer the fund's rank falls in (top layer = best quartile). Funds without a full return history rank only on the horizons they cover.

Similar Funds

See more rows — create a free account▾

Nearest funds across the whole universe, by holdings and behavior — the peer taxonomy is ignored, so matches can come from any category.

Top Similarity62
Top Overlap
Top Active Tilt
Top Factor Match
Top Return Corr
Top FF Match
FundPeer Group
1HQH
abrdn Healthcare Investors
Sector - Biotech
Sector - Biotech
62-----
2FBDIX
Franklin Biotechnology Discovery Fund
Sector - Biotech
Sector - Biotech
38-----
3IBBQ
Invesco Nasdaq Biotechnology ETF
Sector - Biotech
Sector - Biotech
36-----
4IBB
iShares Biotechnology ETF
Sector - Biotech
Sector - Biotech
35-----
5LYFAX
AlphaCentric Life Sciences and Healthcare Fund
Sector - Biotech
Sector - Biotech
33-----
6FBTAX
Fidelity Advisor Biotechnology Fund
Sector - Biotech
Sector - Biotech
33-----
7XBI
State Street(R) SPDR(R) S&P(R) Biotech ETF
Sector - Biotech
Sector - Biotech
33-----
8FBIOX
Select Biotechnology Portfolio
Sector - Biotech
Sector - Biotech
33-----
9THW
abrdn World Healthcare Fund
Sector - Healthcare
Sector - Healthcare
33-----
10FMED
Fidelity Disruptive Medicine ETF
Sector - Healthcare
Sector - Healthcare
27-----

The method columns are members-only — create a free account to see these figures.

ⓘ Methodology

Rows are the consensus top matches (a fund must place in at least two methods' top 250 to qualify, and matches missing more than one of this fund's own methods are not ranked — a row scored on fewer methods is a noisier estimate, not a better match). Click a method column to see that method's own top matches across the whole universe instead. Gray (N) beside each method's metric is that fund's rank in the whole universe on that method. Similarity is a percentile among match-grade fund pairs, 0–100 — 87 means the pair is closer than 87% of the strongest matches in the universe, averaged across the methods — so it compares across funds: index clones tie at the top with thousands of other clone pairs, so scores top out in the high 80s to 90s, while a one-of-a-kind fund's best match can score in the 30s. Rows are ordered by the Consensus Rank — the geometric mean of those universe ranks, shown in each cell's tooltip — and the score is held down the list to the level of the closest match above it, so equal scores mean equally close and the number reads as a floor. A dash means that method has no figure for the pair at all (one of them lacks the holdings or return history it needs). Hover a column header for each method's definition. The “Top…” strips above compare against every fund's own top match across the whole universe (they deliberately don't follow the Peer Universe selector); Top Similarity is simply the best match's score, with no reference band; the Holdings and Active Tilt strips carry no reference band because computing every fund's best book overlap would require a full holdings scan per fund — the dot stands alone on its natural 0–100% scale. One share class shown per fund, and a fund's own sister share classes are excluded from its Top-match strips. Holdings as of 6/30/2026. Consensus Rank is the geometric mean of the match's universe-wide rank across the methods (#1.0 = top match on every one). Holdings Overlap = common-holdings weight (sum of the minimum weight across shared positions, long only). Active Tilt Overlap = the same statistic on active weights (holdings minus the fund's own default benchmark, floored at 0), which strips the benchmark ballast that dominates raw overlap. Factor Similarity = 100 − a signature-weighted RMS gap across the composite factor scores (0–100 ranks within the clean equity fund universe), each axis weighted by how far this fund sits from the universe median of 50. Return Correlation = correlation of market-hedged daily returns over the trailing two years (CAPM residuals), so only market-beta co-movement is removed; requires ~18 months of daily history (378 of the window's 504 trading days). Fama-French Similarity = 1/(1+d), where d is the Euclidean distance between factor betas (market, size, value, profitability, investment, momentum, intangible value) from up to three years of daily returns (min 378 daily observations and regression R² of at least 0.25); 1.00 = identical loadings.